Ipek Erdogan-Trinkaus

Ipek Erdogan-Trinkaus

Chief Commercial OfficeratEton Pharmaceuticals· In proxies 2023–2025

Pay in FY2025-26% from the year before · Eton Pharmaceuticals stock +27.0% the same year

Ipek Erdogan-Trinkaus was paid $575.3K in FY2025 (Dec), down 26%. Eton Pharmaceuticals stock rose 27.0% that year.

Pay$100 in the stock at the end of FY22 → $600
Pay is from the Summary Compensation Table of each Eton Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Eton PharmaceuticalsPublic company · 3 yr
    • Chief Commercial Officer2023 – Present · 3 yrStock in role +1,627%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?